Abstract
Objective To investigate the clinical efficacy of gemcitabine combined with oxaliplatin (GEMOX) on platinum resistant epithelial ovarian cancer. Methods A total of 45 recurrent epithelial ovarian cancer patients were selected.All the patients were treated with gemcitabine(850 mg/m2) on the first and eight day, and oxaliplatin (100 mg/m2) on the first day, three weeks as a therapeutic cyclic, 2-4 therapeutic cycles were performed. The clinical efficacy and adverse reactions were recorded. Results Among the 45 cases, 3 cases of complete remission, 13 cases of partial remission, 20 cases of stable disease, 9 cases of progression of disease. The objective response rate was 35.6%, and the disease control rate was 80.0%. The dose-limiting toxicities were anemia, thrombocytopenia, nausea/nomiting, which were moderate and manageable. Conclusions Gemcitabine combined with oxaliplatin showes obvious clinical efficacy in the treatment of advanced recurrent epithelial ovarian cancer with tolerable adveres effects. Key words: Ovarian cancer; Drug therapy; Platinum resistant
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
